Study on CD19 and CD38 in patients with idiopathic immune thrombocytopenia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202601685673250

Enrollment

100

Registered

2026-01-28

Start date

2025-11-12

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Haematological Disorders

Interventions

laboratory assesment of CD19 and CD38 in healthy controls

laboratory assesment of CD19 and CD38in ITP patients

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -pt with idiopathic immune thrombocytopenia

Exclusion criteria

Exclusion criteria: -seconary causes of immune throbocytopenia and malignancy

Design outcomes

Primary

Measure	Time frame
Primary Outcome: “Difference in CD19 and CD38 expression levels on peripheral blood lymphocytes between patients with idiopathic immune thrombocytopenia and healthy controls at baseline, measured by flow cytometry (% positive cells and mean fluorescence intensity) ,	—

Secondary

Measure	Time frame
1. Correlation between CD19 and CD38 expression levels and platelet count in ITP patients. 2. Comparison of CD19 and CD38 expression between newly diagnosed and chronic ITP patients. 3. Assessment of changes in CD19 and CD38 expression after first-line therapy (optional follow-up at 3 months).	—

Countries

Egypt

Contacts

Public Contactsheren filip Aziz

prof. of clinical pathology

sherenfilip240@gmail.com01227848855

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026